Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T12:01:27.439Z.
Calculation as of: 2026-10-06T12:01:27.439Z.
Quote observation: 2026-10-05T20:00:02.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 370e13d786cc28e63fbc6719e554b7ac483294971c86eef7c80c09e39811c756
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Candel Therapeutics, Inc.
Market Cap
$749.55M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$734.10M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$767.46M
Price/FCF Ratio
N/A
TTM Avg
1186.25
3Y Avg
1180.14
5Y Avg
1180.14
Market Cap
$774.32M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$775.72M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$719.64M
Price/FCF Ratio
N/A
TTM Avg
4.42
3Y Avg
4.41
5Y Avg
4.41
Market Cap
$786.48M
Price/FCF Ratio
N/A
TTM Avg
30.96
3Y Avg
280.40
5Y Avg
522.37
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Candel Therapeutics, Inc. (CADL) | $749.55M | N/A | N/A | N/A | N/A |
| Anteris Technologies Global Corp. (AVR)vs › | $734.10M | N/A | N/A | N/A | N/A |
| Avalo Therapeutics, Inc. (AVTX)vs › | $767.46M | N/A | 1186.25 | 1180.14 | 1180.14 |
| Attovia Therapeutics, Inc. (ATTO)vs › | $774.32M | N/A | N/A | N/A | N/A |
| Design Therapeutics, Inc. (DSGN)vs › | $775.72M | N/A | N/A | N/A | N/A |
| Geron Corporation (GERN)vs › | $776.24M | N/A | 60.32 | 60.32 | 60.32 |
| Achieve Life Sciences, Inc. (ACHV)vs › | $719.64M | N/A | 4.42 | 4.41 | 4.41 |
| AdaptHealth Corp. (AHCO)vs › | $780.95M | 7.99 | 7.03 | 12.33 | 28.28 |
| Cytek Biosciences, Inc. (CTKB)vs › | $786.48M | N/A | 30.96 | 280.40 | 522.37 |
| Collegium Pharmaceutical, Inc. (COLL)vs › | $709.33M | 2.16 | 4.81 | 5.21 | 6.10 |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
